DEFA14A: Novartis Acquires Avidity Neuroscience, Cardiology Spinoff

Novartis AG will acquire Avidity Biosciences' neuroscience programs and RNA-targeting platform, while Avidity's early-stage precision cardiology programs will be spun off into a new public company, SpinCo.

Summary

• Avidity Biosciences, Inc. (Avidity) has entered into a definitive merger agreement to be acquired by Ajax Acquisition Sub, Inc. (Merger Sub), an indirect wholly owned subsidiary of Novartis AG (Novartis).
• Avidity will become an indirect wholly owned subsidiary of Novartis, with the transaction based on an Agreement and Plan of Merger dated October 25, 2025.
• Prior to the merger, Avidity will undergo a pre-closing reorganization, resulting in SpinCo (Bryce Therapeutics, Inc., to be renamed) owning all assets and liabilities related to Avidity's early-stage precision cardiology programs and certain collaboration agreements.
• Avidity will retain all other assets and liabilities, including its neuroscience programs and RNA-targeting delivery platform, which will be acquired by Novartis.
• Following the reorganization, Avidity will either distribute SpinCo Common Stock to its stockholders (1 share of SpinCo per 10 shares of Avidity common stock) or sell SpinCo to a third party.
• After the Spin-Off, Avidity will have no continuing ownership interest in SpinCo.
• Novartis will acquire Avidity's three late-stage clinical development programs: del-zota, del-desiran, and del-brax.
• The Spin-Off includes certain assets that trigger a right of first negotiation with an existing collaboration partner.
• The transactions are expected to close in the first half of 2026.

Sentiment

Score: 8

Explanation: The announcement of an acquisition by a major pharmaceutical company like Novartis for key programs and platform, coupled with a spin-off of other promising assets, is generally a very positive development for a biotech company, indicating validation of its technology and pipeline, and providing significant resources for future development.

Positives

• Avidity's neuroscience programs and RNA-targeting platform gain access to Novartis's extensive global resources, scale, and experience, which is expected to accelerate global regulatory approvals and market entry for del-zota, del-desiran, and del-brax.
• SpinCo will be established as a separate, potentially publicly traded company, allowing for focused development and investment in Avidity's early-stage precision cardiology programs and the AOC platform.
• Avidity stockholders will either receive shares in SpinCo or benefit from its sale, maintaining exposure to the cardiology pipeline while realizing value from the Novartis acquisition.
• Avidity has achieved numerous key milestones, including delivering consistent and reproducible data across its three clinical programs, validating its RNA therapeutics approach.

Negatives

• Avidity, as an independent, integrated company with its full pipeline, will cease to exist post-merger.
• The specific financial terms of the acquisition by Novartis are not disclosed in this filing, making it impossible to assess the immediate financial premium for Avidity shareholders.
• The Spin-Off process involves a complex reorganization and the potential sale of SpinCo to a third party, which could introduce execution uncertainties.

Risks

• The conditions to the closing of the Transactions, including regulatory approvals and Avidity's stockholder approval, may not be satisfied on the expected timetable or at all.
• Risks and costs are associated with the implementation of the SpinCo separation, including the ability to complete the separation in the anticipated timeframe or any changes to the configuration of the businesses included.
• The sale of certain of SpinCo's assets is subject to a third-party right of first negotiation.
• There is a risk that competing offers or acquisition proposals for Avidity may be made.
• The Transactions could cause disruption and impact Novartis and/or Avidity's businesses, including relationships with employees, business partners, or governmental entities.
• The Transactions may be more expensive to complete than anticipated.
• Stockholder litigation in connection with the Transactions may result in significant costs of defense, indemnification, and liability.
• Management's attention may be diverted from ongoing business operations and opportunities due to the Transactions.
• Uncertainties are inherent in research and development, including clinical trial results and additional analysis of existing clinical data.
• Regulatory actions or delays or government regulation generally could affect the outcomes.
• There is no guarantee that Avidity's investigational products will be submitted or approved for sale or for any additional indications or labeling in any market or at any particular time.
• There is no guarantee that Avidity's approach to the discovery and development of product candidates based on its AOC platform will produce any products of commercial value.
• There is no guarantee that the expected benefits or synergies from the Transactions will be achieved in the expected timeframe, or at all.

Future Outlook

Novartis is expected to leverage its global resources and scale to advance Avidity's acquired neuroscience programs (del-zota, del-desiran, del-brax) towards global regulatory approvals and market entry. SpinCo is anticipated to become a publicly traded company, focusing on early-stage precision cardiology programs and continuing to build on the AOC platform. The overall transactions are projected to close in the first half of 2026.

Management Comments

• "Avidity was founded on the bold vision to profoundly improve peoples lives by delivering a new class of RNA therapeutics."
• "We have made incredible strides as the first-ever company to successfully demonstrate the targeted delivery of RNA to muscle."
• "Just this year, we have achieved numerous key milestones — most importantly, delivering consistent and reproducible data across our three clinical programs and setting the stage to deliver del-zota, del-desiran and del-brax to people waiting for treatment."
• "We are confident that under Novartis ownership and with the benefit of its greater resources and global scale, del-zota, del-desiran and del-brax will be well-positioned for global regulatory approvals and market entry worldwide."
• "We are energized by the opportunity ahead to continue building on our groundbreaking AOC platform with the potential to address high unmet need in cardiovascular diseases."
• "While this announcement marks an exciting new phase for Avidity, today is just day one."
• "We expect the transactions to close in the first half of 2026."
• "Until then, Avidity will continue to operate as a separate and independent company."
• "Throughout this process and following close, we will be working closely with Novartis to make this transition as seamless as possible for our stakeholders."

Industry Context

This transaction underscores the increasing strategic value of RNA therapeutics platforms and late-stage clinical assets in specialized areas like neuroscience within the biotechnology sector. Large pharmaceutical companies, such as Novartis, are actively pursuing acquisitions of innovative biotech firms to enhance their pipelines and technological capabilities. The concurrent spin-off of early-stage assets into a new, focused entity is a common strategy to unlock value and enable specialized development for distinct therapeutic areas, reflecting a dynamic M&A landscape in the pharmaceutical industry.

Comparison to Industry Standards

• The acquisition of a biotech company with a validated RNA-targeting delivery platform and late-stage clinical assets by a major pharmaceutical company like Novartis aligns with prevailing industry trends where large pharma seeks to bolster its pipeline through strategic M&A.
• The spin-off of non-core, early-stage assets (precision cardiology programs) into a separate, potentially publicly traded entity (SpinCo) is a recognized strategy for value creation, allowing each entity to pursue distinct strategic objectives and attract specialized investment, similar to other biotech carve-outs.
• The focus on RNA therapeutics, particularly for targeted delivery to muscle, positions Avidity within a high-growth area in biotechnology, building on the success of other companies in gene therapy and RNA interference, and indicating a strong market appetite for such innovative platforms.

Management Changes

Corporate Governance

Legal Proceedings

• There is a risk of stockholder litigation in connection with the Transactions, which may result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders: Will receive consideration for Avidity shares (implied by merger) and potentially shares in SpinCo, or benefit from SpinCo's sale, gaining exposure to Novartis's resources for neuroscience programs and continued investment in cardiology via SpinCo.
• Employees: Avidity will continue to operate independently until closing, implying a transition period. The future structure for employees in the acquired neuroscience division and SpinCo is not fully detailed but implies changes.
• Customers/Patients: The acquisition by Novartis is presented as a positive for patients, potentially accelerating global regulatory approvals and market entry for del-zota, del-desiran, and del-brax due to Novartis's greater resources and global reach.
• Business Partners: Existing collaboration partners, particularly those with a right of first negotiation for SpinCo assets, are directly impacted. Novartis's global scale could expand opportunities for partners involved with the acquired programs.

Next Steps

• Avidity, Novartis, and SpinCo intend to file relevant documents with the SEC, including preliminary and definitive proxy statements.
• A definitive proxy statement and proxy card will be delivered to Avidity stockholders in advance of a special meeting relating to the Transactions.
• Avidity will continue to operate as a separate and independent company until the transactions close.
• Avidity will work closely with Novartis to ensure a seamless transition for stakeholders.
• SpinCo will be led by Kathleen Gallagher as Chief Executive Officer and Sarah Boyce as Chair of the Board upon the Spin-Off.

Key Dates

Recommendation

The acquisition of Avidity's core neuroscience assets and platform by a global pharmaceutical giant like Novartis provides significant validation of Avidity's technology and late-stage pipeline. This typically results in a substantial premium for shareholders. Furthermore, the spin-off of the early-stage precision cardiology programs into a new, potentially publicly traded entity (SpinCo) allows Avidity shareholders to retain exposure to this promising, high-growth area, effectively creating two distinct value propositions. This dual outcome mitigates risk and maximizes potential returns, making it a strong buy for investors.

Keywords

Avidity Biosciences, Novartis, Merger, Acquisition, Spin-Off, RNA therapeutics, Neuroscience, Cardiology, del-zota, del-desiran, del-brax, AOC platform, Biotechnology, Pharmaceutical